Weight Reversal Post Tirzepatide Withdrawal
From Eagle's Eye View: Your Weekly CV Update From ACC.org · · 8 min
This plays from the publisher's own server. We do not host a copy.
Description
In this week's View, Dr. Eagle looks at the DANISH trial extended follow-up, evaluating which patients benefit most from primary prevention implantable cardioverter defibrillator (ICD) implantation. He then explores the SURMOUNT-4 study on weight reversal post tirzepatide withdrawal. Finally, Dr. Eagle examines two JACC articles that cover disease monitoring: one tracking the progression of transthyretin amyloid cardiomyopathy (ATTR-CM) and another assessing cardiovascular risks in patients receiving cancer therapy.
Subscribe to Eagle's Eye View
Back to Eagle's Eye View: Your Weekly CV Update From ACC.org · Report a problem